Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/29995
Title: | Chronological Trends in Progression-Free, Overall, and Post-Progression Survival in First-Line Therapy for Advanced NSCLC | Authors: | Rutkowski, Jacek Saad, Everardo D. BURZYKOWSKI, Tomasz BUYSE, Marc Jassem, Jacek |
Issue Date: | 2019 | Publisher: | ELSEVIER SCIENCE INC | Source: | JOURNAL OF THORACIC ONCOLOGY, 14(9), p. 1619-1627 | Abstract: | Background: There is a debate about the merits of progression-free survival (PFS) versus overall survival (OS) as primary endpoints in NSCLC. It has been postulated that post-progression therapy may influence OS in both arms. To investigate this issue, we analyzed chronological trends in PFS and OS in advanced NSCLC using restricted mean survival times (RMSTs). Methods: We digitized survival curves from first-line phase III trials published between 1998 and 2015 in 13 leading journals to compute RMSTs for PFS and OS at three truncation landmarks (5, 12, and 18 months). Results: Among the 161 trials identified, RMSTs could be computed for both endpoints in 102, 97, and 82 trials for the 5-, 12-, and 18-month truncation landmarks, respectively. Post-progression survival in the control arm, quantified as mean OS minus mean PFS truncated at 18 months, was on average 3.3 months between 1998 and 2003, 4.4 months between 2004 and 2009, and 5.4 months between 2010 and 2015. This increase was due to increasing RMST for OS over time, with no increase in RMST for PFS. The average within-trial difference in RMSTs between experimental and control arm was close to 0 for OS and less than 1 month for PFS. Conclusions: There is a progressive increase in post-progression survival in NSCLC trials, likely from salvage therapy. These results question both PFS and OS as sensitive endpoints in first-line trials, but suggest that the outlook for patients is improving regardless of within-trial gains. | Notes: | [Rutkowski, Jacek; Jassem, Jacek] Med Univ Gdansk, Gdansk, Poland. [Saad, Everardo D.] Dendrix Res, Sao Paulo, Brazil. [Saad, Everardo D.; Burzykowski, Tomasz] Int Drug Dev Inst, Louvain La Neuve, Belgium. [Burzykowski, Tomasz; Buyse, Marc] Hasselt Univ, Interuniv Inst Biostat & Stat Bioinformat I BioSt, Diepenbeek, Belgium. [Buyse, Marc] Int Drug Dev Inst, San Francisco, CA USA. | Keywords: | Lung cancer; Overall survival; Progression-free survival; Post-progression survival;Lung cancer; Overall survival; Progression-free survival; Post-progression survival | Document URI: | http://hdl.handle.net/1942/29995 | ISSN: | 1556-0864 | e-ISSN: | 1556-1380 | DOI: | 10.1016/j.jtho.2019.05.030 | ISI #: | 000482190300031 | Rights: | 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved. | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2020 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
rutkowski2019.pdf Restricted Access | Published version | 392.81 kB | Adobe PDF | View/Open Request a copy |
PIIS1556086419304150.pdf | Peer-reviewed author version | 620.11 kB | Adobe PDF | View/Open |
SCOPUSTM
Citations
1
checked on Sep 3, 2020
WEB OF SCIENCETM
Citations
13
checked on Apr 22, 2024
Page view(s)
80
checked on Sep 7, 2022
Download(s)
98
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.